Zhaoke Ophthalmology Launches Preservative-Free Glaucoma Drug

Zhaoke Ophthalmology Ltd. (HK:6622) has released an update.

Zhaoke Ophthalmology Ltd. has announced the National Medical Products Administration’s approval of its Bimatoprost eye drop, a preservative-free treatment for glaucoma, marking it as China’s first single-dose bimatoprost eye drop without preservatives. The product aims to improve patient comfort and compliance by reducing the long-term side effects associated with preservatives found in other treatments. This development is particularly significant given the high prevalence of glaucoma in China, which accounts for about a quarter of the global patient population.

For further insights into HK:6622 stock, check out TipRanks’ Stock Analysis page.